Entera Bio Ltd. appointed Geno J. Germano as Director and Chairman of the Board on February 4, 2026, following the resignation of Gerald Lieberman, effective immediately. Mr. Germano brings 35 years of pharmaceutical experience, previously leading a $14 billion portfolio at Pfizer, while the sentiment of this event is neutral and considered significant by equity investors.